Ozurdex dexamethasone intravitreal implant regulatory update

EMA’s CHMP recommended expanding the label of Ozurdex dexamethasone intravitreal implant to include treatment of visual impairment due to diabetic macular edema (DME) in adults who are pseudophakic --...